Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe and Sanitary Processing and Importing of Fish and Fishery Products, 10222-10224 [E7-3915]
Download as PDF
<![CDATA[
10222
Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices
NFP for a lasagna product and has
revised the NFPs for the lasagna pairs.
In addition, FDA changed a product
category from cookies to donuts edited
and the NFPs for the new donut product
pair to add a disclosure of cholesterol.
(Comment 5) One comment critiqued
the draft Full Information treatment
language. The comment criticized the
one-page summary because: (1) It did
not identify calories in the discussion of
fat as a major source of energy and (2)
it did not relate the calorie contribution
of fat to that of carbohydrates and
protein. The comment also criticized the
information about sources of trans fat
because it omitted mention of natural
sources of trans fat in the diet, which
the comment suggested would help
ensure factually correct and balanced
information about sources of trans in the
diet. The comment questioned the value
of stating that trans fat extends shelflife
and has desirable taste characteristics
since many saturated fat sources are
relatively shelf stable and have desirable
taste characteristics.
(Response) FDA agrees and has
revised the Full Information treatment
in response to these concerns. Calories
and other sources of energy are now
mentioned in the introductory passage.
Natural sources of trans fat are now
mentioned and the similarity between
trans fat and saturated fat in terms of
shelflife and taste are now addressed.
The revised draft will be included in the
study pretest and further revisions will
be made if FDA determines they are
needed based upon pretest results.
(Comment 6) One comment suggested
consumer confusion may be caused
when a NFP for a product discloses 0g
of trans fat but the ingredient list
discloses an ingredient that contains
trans fat, as is permitted by the trans fat
labeling regulations. The comment
concluded that FDA should add
experimental conditions in which this
occurs. The comment suggested that for
this situation the study should test
language for a footnote to the ingredient
list to explain that there may be a trans
fat ingredient in the product when the
NFP shows trans fat as zero.
(Response) FDA disagrees with the
proposed addition to the study’s
experimental conditions. Under existing
trans fat labeling regulations, food
manufacturers are allowed to list
amounts of trans fat less than 0.5 g per
serving as zero on the NFP. While such
situations occur in the marketplace and
are permitted by the trans fat labeling
regulations, whether this causes
consumer confusion is an issue outside
the scope of the proposed research,
which focuses on the effects of NFP
footnotes and alternative presentations
of trans fat information in the NFP on
consumers’ ability to correctly identify
more healthful food products. The
Office of Nutritional Products, Labeling,
and Dietary Supplements has received
and responded to a separate letter on
this topic from the commenter.
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Activity
Pretest
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
40
1
40
.25
10
3,240
Study
1
3,240
.25
810
Total
820
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: February 28, 2007.
Jeffrey Shuren,
Associate Commissioner for Policy.
[FR Doc. E7–3904 Filed 3–6–07; 8:45 am]
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
Fax written comments on the
collection of information by April 6,
2007.
DATES:
BILLING CODE 4160–01–S
To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
ADDRESSES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N–0357]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Procedures for the
Safe and Sanitary Processing and
Importing of Fish and Fishery Products
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Total Hours
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
VerDate Aug<31>2005
18:25 Mar 06, 2007
Jkt 211001
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
4659.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00111
Fmt 4703
Sfmt 4703
Procedures for the Safe and Sanitary
Processing and Importing of Fish and
Fishery Products—21 CFR Part 123
(OMB Control Number 0910–0354)—
Extension
FDA regulations in part 123 (21 CFR
part 123) mandate the application of
hazard analysis and critical control
point (HACCP) principles to the
processing of seafood. HACCP is a
preventive system of hazard control
designed to help ensure the safety of
foods. The regulations were issued
under FDA’s statutory authority to
regulate food safety, including section
402(a)(1) and (a)(4) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C.
342(a)(1) and (a)(4)), and became
effective on December 18, 1997.
Certain provisions in part 123 require
that processors and importers of seafood
collect and record information. The
HACCP records compiled and
maintained by a seafood processor
primarily consist of the periodic
observations recorded at selected
monitoring points during processing
and packaging operations, as called for
in a processor’s HACCP plan (e.g., the
E:\FR\FM\07MRN1.SGM
07MRN1
Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices
values for processing times,
temperatures, acidity, etc., as observed
at critical control points). The primary
purpose of HACCP records is to permit
a processor to verify that products have
been produced within carefully
established processing parameters
(critical limits) that ensure that hazards
have been avoided. HACCP records are
normally reviewed by appropriately
trained employees at the end of a
production lot or at the end of a day or
week of production to verify that control
limits have been maintained, or that
appropriate corrective actions were
taken if the critical limits were not
maintained. Such verification activities
are essential to ensure that the HACCP
system is working as planned. A review
of these records during the conduct of
periodic plant inspections also permits
FDA to determine whether the products
have been consistently processed in
conformance with appropriate HACCP
food safety controls.
Section 123.12 requires that importers
of seafood products take affirmative
steps and maintain records that verify
that the fish and fishery products they
offer for import into the United States
were processed in accordance with the
HACCP and sanitation provisions set
forth in part 123. These records are also
to be made available for review by FDA
as provided in § 123.12(c).
The time and costs of these
recordkeeping activities will vary
considerably among processors and
importers of fish and fishery products,
depending on the type and number of
products involved, and on the nature of
the equipment or instruments required
to monitor critical control points. The
burdens have been estimated using
typical small seafood processing firms
as a model because these firms represent
a significant proportion of the industry.
Costs were estimated for the collection
of HACCP data for each type of
recordkeeping activity using a labor cost
of $15.00 per hour.
10223
The burden estimate in table 1 of this
document includes only those
collections of information under the
seafood HACCP regulations that are not
already required under other statutes
and regulations. The estimate also does
not include collections of information
that are a usual and customary part of
businesses’ normal activities. For
example, the tagging and labeling of
molluscan shellfish (21 CFR 1240.60) is
a customary and usual practice among
seafood processors. Consequently, the
estimates in table 1 of this document
account only for information collection
and recording requirements attributable
to part 123.
Upon reevaluation of the burden
estimates for part 123, we have
determined that PRA requirements do
not apply to § 123.10.
In the Federal Register of September
26, 2006 (71 FR 56154), FDA published
a 60-day notice requesting public
comment on the information collection
provisions. No comments were received.
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section2
No. of
Recordkeepers
123.6(a), (b), and (c)
Annual Frequency
per Recordkeeping3
Total Annual
Records
Hours per
Record4
Total Hours
275
1
275
16.00
4,400
123.6(c)(5)
5,500
4
22,000
0.30
6,600
123.8(a)(1) and (c)
5,500
1
5,500
4.00
22,000
123.12(a)(2)(ii)
1,100
80
88,000
0.20
17,600
123.6(c)(7)
5,500
280
1,540,000
0.30
462,000
123.7(d)
2,200
4
8,800
0.10
880
123.8(d)
5,500
47
258,500
0.10
25,850
123.11(c)
5,500
280
1,540,000
0.10
154,000
123.12(c)
1,100
80
88,000
0.10
8,800
55
1
55
4.00
220
123.12(a)(2)
TOTAL
702,350
1There
sroberts on PROD1PC70 with NOTICES
are no capital costs or operating and maintenance costs associated with this collection of information.
2These estimates include the information collection requirements in the following sections:
§ 123.16—Smoked Fish—process controls (see § 123.6(b))
§ 123.28(a)—Source Controls—molluscan shellfish (see § 123.6(b))
§ 123.28(c) and (d)—Records–molluscan shellfish (see § 123.6(c)(7))
3Based on an estimated 280 working days per year.
4Estimated average time per 8-hour workday unless one-time response.
VerDate Aug<31>2005
18:25 Mar 06, 2007
Jkt 211001
PO 00000
Frm 00112
Fmt 4703
Sfmt 4703
E:\FR\FM\07MRN1.SGM
07MRN1
10224
Federal Register / Vol. 72, No. 44 / Wednesday, March 7, 2007 / Notices
Dated: February 27, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–3915 Filed 3–6–07; 8:45 am]
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–443–5570.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0062]
Guidance on Drug Safety
Information—Food and Drug
Administration’s Communication to
the Public; Availability
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance titled ‘‘Drug
Safety Information—FDA’s
Communication to the Public.’’ This
guidance describes FDA’s current
approach to communicating important
drug safety information, including
emerging drug safety information, to the
public and the factors that influence
when such information is
communicated. This guidance was
developed in connection with FDA’s
Drug Safety Initiative. This guidance is
the final version and supersedes the
previously issued draft guidance titled
‘‘FDA’s Drug Watch for Emerging Drug
Safety Information’’ (70 FR 24606, May
10, 2005).
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information (HFD–
240), Center for Drug Evaluation and
Research, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT: Paul
J. Seligman, Associate Director for
Safety Policy and Communication,
Center for Drug Evaluation and Research
(HFD–001), Food and Drug
VerDate Aug<31>2005
18:25 Mar 06, 2007
Jkt 211001
I. Background
FDA is announcing the availability of
a guidance entitled ‘‘Drug Safety
Information—FDA’s Communication to
the Public.’’ This guidance describes
FDA’s current approach to
communicating important drug safety
information, including emerging drug
safety information, to the public and the
factors that influence when such
information is communicated.
For many years, FDA has provided
information on drug risks and benefits
to healthcare professionals and patients
when that information has generated a
specific concern or prompted a
regulatory action, such as a revision to
the drug product’s labeling. FDA has
been reexamining its risk
communication program, including how
and when we communicate emerging
drug safety information to the public.
More recently, FDA has begun taking a
more comprehensive approach to
making information on potential drug
risks available to the public earlier, in
some cases while the agency still is
evaluating whether any regulatory
action is warranted. FDA believes that
timely communication of important
drug safety information will give
healthcare professionals, patients,
consumers, and other interested persons
access to the most current information
concerning the potential risks and
benefits of a marketed drug, helping
them to make more informed individual
treatment choices.
FDA’s risk communication efforts are
part of a larger drug safety initiative that
began in November 2004, when FDA
announced an initiative to strengthen
the safety program for marketed drugs.
This initiative included the following:
(1) Sponsoring an independent study by
the Institute of Medicine of the National
Academies of the effectiveness of the
drug safety system, with emphasis on
postmarketing risk assessment and
surveillance; (2) conducting workshops
and Advisory Committee meetings
regarding complex drug safety and risk
management issues, including emerging
concerns; and (3) publishing three risk
management guidances. FDA
augmented its drug safety initiative in
February 2005 by creating an
independent Drug Safety Oversight
Board to enhance oversight of drug
safety decision making within the
Center for Drug Evaluation and Research
(CDER).
In May 2005, FDA issued a draft
guidance titled ‘‘FDA’s Drug Watch for
Emerging Drug Safety Information’’ (70
PO 00000
Frm 00113
Fmt 4703
Sfmt 4703
FR 24606, May 10, 2005). The draft
guidance described a proposal to
establish a new communication
channel, called the ‘‘Drug Watch’’ Web
page, to provide information to the
public on emerging drug safety issues.
In December 2005, FDA held a public
hearing regarding ‘‘FDA’s
Communication of Drug Safety
Information’’ that examined the various
risk communication tools employed by
FDA. FDA has carefully reviewed the
comments it received on the draft
guidance (30 comments were submitted
to the public docket) and during the
public hearing. This final version of the
guidance reflects our consideration of
these comments, as well as our
experience with posting emerging drug
safety information.
Due to potential confusion between
the proposed ‘‘Drug Watch’’ and FDA’s
existing ‘‘MedWatch’’ program, FDA no
longer plans to use the name ‘‘Drug
Watch’’ to describe the Web page that
contains drug safety information. We
have identified drugs that have been the
subject of a Public Health Advisory or
an Alert on a single Web page, the Index
to Drug-Specific Information, linked
from FDA’s Web site. This is part of our
ongoing effort to use and enhance
existing FDA communications
mechanisms to better convey important
drug safety information to the public. In
addition, we have revised this guidance
to describe the various methods FDA
currently uses to communicate
established and emerging drug safety
information to the public. It should be
noted that we will continue to evaluate
and enhance the effectiveness of the
various methods we use to
communicate about important drug
safety issues, including the mechanisms
described in this guidance and the
presentation of drug safety information
on the Agency Web sites (https://
www.fda.gov and https://www.fda.gov/
cder). We intend to update this
guidance, as appropriate, to reflect any
substantial modifications to our
communication of drug safety
information to the public.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on this topic. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
E:\FR\FM\07MRN1.SGM
07MRN1
]]>Agencies
[Federal Register Volume 72, Number 44 (Wednesday, March 7, 2007)]
[Notices]
[Pages 10222-10224]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3915]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0357]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Procedures for the
Safe and Sanitary Processing and Importing of Fish and Fishery Products
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by April
6, 2007.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief
Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-4659.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Procedures for the Safe and Sanitary Processing and Importing of Fish
and Fishery Products--21 CFR Part 123 (OMB Control Number 0910-0354)--
Extension
FDA regulations in part 123 (21 CFR part 123) mandate the
application of hazard analysis and critical control point (HACCP)
principles to the processing of seafood. HACCP is a preventive system
of hazard control designed to help ensure the safety of foods. The
regulations were issued under FDA's statutory authority to regulate
food safety, including section 402(a)(1) and (a)(4) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 342(a)(1) and (a)(4)), and
became effective on December 18, 1997.
Certain provisions in part 123 require that processors and
importers of seafood collect and record information. The HACCP records
compiled and maintained by a seafood processor primarily consist of the
periodic observations recorded at selected monitoring points during
processing and packaging operations, as called for in a processor's
HACCP plan (e.g., the
[[Page 10223]]
values for processing times, temperatures, acidity, etc., as observed
at critical control points). The primary purpose of HACCP records is to
permit a processor to verify that products have been produced within
carefully established processing parameters (critical limits) that
ensure that hazards have been avoided. HACCP records are normally
reviewed by appropriately trained employees at the end of a production
lot or at the end of a day or week of production to verify that control
limits have been maintained, or that appropriate corrective actions
were taken if the critical limits were not maintained. Such
verification activities are essential to ensure that the HACCP system
is working as planned. A review of these records during the conduct of
periodic plant inspections also permits FDA to determine whether the
products have been consistently processed in conformance with
appropriate HACCP food safety controls.
Section 123.12 requires that importers of seafood products take
affirmative steps and maintain records that verify that the fish and
fishery products they offer for import into the United States were
processed in accordance with the HACCP and sanitation provisions set
forth in part 123. These records are also to be made available for
review by FDA as provided in Sec. 123.12(c).
The time and costs of these recordkeeping activities will vary
considerably among processors and importers of fish and fishery
products, depending on the type and number of products involved, and on
the nature of the equipment or instruments required to monitor critical
control points. The burdens have been estimated using typical small
seafood processing firms as a model because these firms represent a
significant proportion of the industry. Costs were estimated for the
collection of HACCP data for each type of recordkeeping activity using
a labor cost of $15.00 per hour.
The burden estimate in table 1 of this document includes only those
collections of information under the seafood HACCP regulations that are
not already required under other statutes and regulations. The estimate
also does not include collections of information that are a usual and
customary part of businesses' normal activities. For example, the
tagging and labeling of molluscan shellfish (21 CFR 1240.60) is a
customary and usual practice among seafood processors. Consequently,
the estimates in table 1 of this document account only for information
collection and recording requirements attributable to part 123.
Upon reevaluation of the burden estimates for part 123, we have
determined that PRA requirements do not apply to Sec. 123.10.
In the Federal Register of September 26, 2006 (71 FR 56154), FDA
published a 60-day notice requesting public comment on the information
collection provisions. No comments were received.
Table 1.--Estimated Annual Recordkeeping Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
21 CFR Section\2\ Recordkeepers per Recordkeeping\3\ Records Record\4\ Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.6(a), (b), and (c) 275 1 275 16.00 4,400
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.6(c)(5) 5,500 4 22,000 0.30 6,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.8(a)(1) and (c) 5,500 1 5,500 4.00 22,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.12(a)(2)(ii) 1,100 80 88,000 0.20 17,600
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.6(c)(7) 5,500 280 1,540,000 0.30 462,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.7(d) 2,200 4 8,800 0.10 880
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.8(d) 5,500 47 258,500 0.10 25,850
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.11(c) 5,500 280 1,540,000 0.10 154,000
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.12(c) 1,100 80 88,000 0.10 8,800
--------------------------------------------------------------------------------------------------------------------------------------------------------
123.12(a)(2) 55 1 55 4.00 220
--------------------------------------------------------------------------------------------------------------------------------------------------------
TOTAL 702,350
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
\2\These estimates include the information collection requirements in the following sections:
Sec. 123.16--Smoked Fish--process controls (see Sec. 123.6(b))
Sec. 123.28(a)--Source Controls--molluscan shellfish (see Sec. 123.6(b))
Sec. 123.28(c) and (d)--Records-molluscan shellfish (see Sec. 123.6(c)(7))
\3\Based on an estimated 280 working days per year.
\4\Estimated average time per 8-hour workday unless one-time response.
[[Page 10224]]
Dated: February 27, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-3915 Filed 3-6-07; 8:45 am]
BILLING CODE 4160-01-S
